Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.
What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.